FY2027 Earnings Forecast for Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Issued By Leerink Partnrs

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Investment analysts at Leerink Partnrs issued their FY2027 earnings estimates for Zentalis Pharmaceuticals in a report released on Wednesday, July 24th. Leerink Partnrs analyst A. Berens expects that the company will post earnings per share of ($3.38) for the year. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.72) per share.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its earnings results on Tuesday, May 7th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.91. The company had revenue of $40.56 million for the quarter, compared to analyst estimates of $35.00 million. During the same period last year, the business earned ($1.07) EPS.

Several other research analysts also recently commented on ZNTL. HC Wainwright dropped their target price on shares of Zentalis Pharmaceuticals from $40.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, June 18th. UBS Group lowered Zentalis Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $28.00 to $5.00 in a research note on Thursday, June 20th. Wells Fargo & Company cut shares of Zentalis Pharmaceuticals from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $29.00 to $9.00 in a research note on Tuesday, June 18th. Stifel Nicolaus decreased their price target on Zentalis Pharmaceuticals from $32.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, June 18th. Finally, Wedbush downgraded Zentalis Pharmaceuticals from a “neutral” rating to an “underperform” rating and cut their price objective for the company from $15.00 to $4.00 in a research report on Tuesday, June 18th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $11.33.

Zentalis Pharmaceuticals Stock Performance

Shares of NASDAQ ZNTL opened at $4.12 on Monday. The business has a 50 day simple moving average of $6.69 and a 200 day simple moving average of $10.92. Zentalis Pharmaceuticals has a 52 week low of $3.27 and a 52 week high of $29.03. The stock has a market cap of $292.64 million, a price-to-earnings ratio of -1.24 and a beta of 1.71.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of ZNTL. ProShare Advisors LLC increased its holdings in Zentalis Pharmaceuticals by 9.0% in the 1st quarter. ProShare Advisors LLC now owns 15,436 shares of the company’s stock valued at $243,000 after buying an additional 1,274 shares during the period. Quest Partners LLC acquired a new position in shares of Zentalis Pharmaceuticals in the fourth quarter worth approximately $38,000. Tower Research Capital LLC TRC lifted its position in shares of Zentalis Pharmaceuticals by 252.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,615 shares of the company’s stock worth $55,000 after purchasing an additional 2,589 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Zentalis Pharmaceuticals by 0.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 445,823 shares of the company’s stock worth $6,754,000 after acquiring an additional 3,759 shares in the last quarter. Finally, Values First Advisors Inc. grew its holdings in Zentalis Pharmaceuticals by 5.4% in the second quarter. Values First Advisors Inc. now owns 74,925 shares of the company’s stock worth $306,000 after purchasing an additional 3,859 shares during the period.

Insider Transactions at Zentalis Pharmaceuticals

In related news, insider Diana Hausman sold 3,356 shares of the firm’s stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $12.62, for a total value of $42,352.72. Following the completion of the transaction, the insider now owns 373,876 shares of the company’s stock, valued at $4,718,315.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Zentalis Pharmaceuticals news, insider Diana Hausman sold 3,356 shares of the company’s stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $12.62, for a total transaction of $42,352.72. Following the sale, the insider now directly owns 373,876 shares of the company’s stock, valued at $4,718,315.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Cam Gallagher sold 9,597 shares of the stock in a transaction on Friday, May 31st. The shares were sold at an average price of $11.98, for a total value of $114,972.06. Following the completion of the sale, the chief financial officer now owns 633,680 shares in the company, valued at approximately $7,591,486.40. The disclosure for this sale can be found here. 6.10% of the stock is owned by insiders.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.